1,540 Against a 4,000 Milestone
A Phase 3 vaccine trial plans 30 sites and 6,000 participants over 12 months. At Month 9: 12 sites are open, 1,540 participants are enrolled against a 4,000 milestone, screen failure is 41% against the 18% assumed in feasibility, and per-participant payments are triggered only at database lock. The two highest-enrolling sites are investigator-owned private clinics that also run three competing vaccine trials. The lead clinical research coordinator at your largest academic site resigned six weeks ago, and 14 delegation logs have not been updated since startup. The sponsor is considering opening 20 additional sites to close the gap. You are the sponsor's clinical trial manager.
1. Where will the next 90 days of enrollment come from: adding 20 sites, or fixing the 12 already open? Show your reasoning.
Read the worked answer
Fixing what is already open, by a wide margin.
Run the arithmetic. Twelve sites delivered 1,540 participants in roughly six months of average enrollment-about 21 participants per site-month, already above many vaccine benchmarks. A new site in a vaccine trial needs 8 to 12 weeks to reach first participant (contract, IRB, site initiation, training) and another 4 to 8 weeks to build a screening pipeline. Twenty new sites would contribute close to zero inside 90 days while consuming the operational team's attention.
Find the real constraint: the screen-failure rate. 41% against 18% assumed is where the lost enrollment lives. If the 1,540 enrollees represent 59% of screened participants, then roughly 1,070 people were screened out-more than the entire shortfall. Diagnose before acting: pull the screen-failure log and tabulate reasons. If one or two eligibility criteria dominate, ask whether sites are applying them correctly or whether the criteria are genuinely over-restrictive for the population.
Then act in order: prescreening logs and a shared prescreen script; a feasibility re-check on the 18 unopened sites to decide how many are worth activating; concentration on the six best-pipeline sites; and an honest re-forecast with the medical and statistical leads. If a criterion is systematically excluding the intended population, that is a protocol design question requiring a formal amendment and regulatory discussion-not a quiet relaxation at site level.
2. The payment model is part of the problem. What do you propose, and how do you keep it budget-neutral?
Read the worked answer
The current design is generating the behavior you are seeing.
Paying only at database lock means a site finances the trial for 12 to 18 months. A private clinic running four competing vaccine trials will allocate coordinators to whichever study pays as it enrolls. Your sites are not behaving irrationally; they are responding to your cash-flow design.
Proposed restructure, keeping total per-participant value constant:
- A startup and activation payment covering IRB fees, contract execution, and staff training-this rewards sites for getting open, which is currently the binding constraint.
- Per-participant milestone payments at screening, randomization, and each completed visit, invoiced and paid net-30, triggered from the EDC enrollment report rather than a manual reconciliation.
- A holdback of 10 to 15% released at database lock to preserve data-quality incentives.
Budget neutrality holds because the sum is unchanged; only the timing moves. Expect negotiation on the holdback and on invoice triggers-accept a shorter holdback rather than a manual invoicing process, which reintroduces delay and dispute.
Separately: cap enrollment at the two over-committed private clinics at a level they can actually staff, agreed in a contract amendment. Pushing them harder produces screen-failure inflation and data quality problems, not participants.
3. How do you handle the 14 stale delegation logs and the coordinator vacancy at your largest site?
Read the worked answer
These are one risk with two faces: tasks being performed by people with no documented qualification for them.
Delegation logs. Fourteen logs unchanged since startup means staff have joined, left, or changed roles without documentation. The safety-relevant edge: if an undelegated person performed a trial procedure or obtained consent, the data and the consent become contestable. Immediate action-issue a 7-day requirement for each of the 14 sites to return a signed, complete log listing every person who touches the trial and the specific tasks each performs. Then cross-check against sources the log cannot fake: consent forms, EDC user lists, lab requisitions, and dispensing records. Reconcile the differences, then remediate with documented protocol-specific training.
The vacancy. A coordinator resigned six weeks ago, which means somebody has been running visits. Determine who, and whether they are delegated and trained. Provide sponsor-funded interim coverage-a shared regional coordinator for 60 to 90 days-and require every site to name a trained backup on its log.
Sustainability. Make delegation review a standing agenda item at each monitoring visit, and require the PI to sign log updates whenever staffing changes rather than annually. Unannounced cross-checks of EDC users against the log catch drift between visits.